Another new entry point for the treatment of NAFLD is the NR4A1 (nuclear receptor subfamily four group A member 1)/DNA-PKcs (DNA-dependent protein kinase catalytic subunit)/p53 pathway. The gene discussed is PRKDC; the disease is metabolic dysfunction-associated steatotic liver disease.